Publicly insured children less likely to receive nirsevimab for RSV

Children in Massachusetts who were publicly insured or living in less affluent ZIP codes were less likely to receive nirsevimab, a monoclonal antibody for respiratory syncytial virus, according to research published in Pediatrics.
RSV is the leading cause of hospitalization for infants in the United States. Last year two new RSV immunizations came on the market for infants, including a maternal vaccine and nirsevimab, which the AAP recommends for all young infants.
“Understanding which primary care practices and patient populations are likely to be early adopters of a new immunization can

Children in Massachusetts who were publicly insured or living in less affluent ZIP codes were less likely to receive nirsevimab, a monoclonal antibody for respiratory syncytial virus, according to research published in Pediatrics.
RSV is the leading cause of hospitalization for infants in the United States. Last year two new RSV immunizations came on the market for infants, including a maternal vaccine and nirsevimab, which the AAP recommends for all young infants.
“Understanding which primary care practices and patient populations are likely to be early adopters of a new immunization can